AzTrials
AzTrials

ElderlyGOSAFENCT03299270

Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery

An observational study of Elderly and Solid Malignancy, run by AUSL ROMAGNA at 28 sites in 10 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Multicenter, international, prospective, observational study, designed to evaluate the postoperative results in terms of quality of life and functional recovery of elderly patients after major cancer surgery. Read more about this study

Who is it for?
Ages 70 years and older
Conditions the study is for
Elderly, Solid Malignancy
What is being tested?
Questionnaires
How many people
1,004 participants
Where
28 sitesin 10 countries
Study dates
27 Feb 2017to Feb 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 70 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Centers should ensure that they would make every possible effort to include all consecutive eligible patients during the study period and provide completeness of data entry to ensure a 'real-life' study.

Who may be able to join

  • All consecutive patients, both gender, aged ≥70
  • Patients affected by solid malignancy
  • Patients undergoing elective major surgical procedures with curative or palliative intent (all major procedures including any resection, for any cancer, via any operative approach, open, laparoscopic, robotic, etc…)
  • Informed consent obtainment

Who cannot join

  • Patients undergoing emergent/urgent surgical procedures
  • Planned hospital stay less than 48 hours

Trial locations and contacts

28 sites in 10 countries.

28 sites in 10 countries

Italy13 sites
  • IstitutoTumori Giovanni Paolo II

    Bari, Apulia, 70121

  • Ospedale di Desio

    Desio, Monza E Brianza, 20039

  • General Surgery Unit

    Faenza, Ravenna, 48018

  • Ospedale di Forlì

    Forlì, Forli-Cesena, 47121

  • IRCCS Ospedale S. Martino Genova, Chirurgia Generale ad indirizzo oncologico

    Genoa, Liguria, 16121

  • IRCCS Ospedale S. Martino Genova, Clinica Chirurgica 1

    Genoa, Liguria, 16121

  • Ospedale Niguarda

    Milan, 20162

  • Ospedale di Piacenza

    Piacenza, 29121

  • Ospedale di Riccione

    Riccione, Rimini, 47838

  • Ospedale S. Andrea

    Rome, Lazio, 00100

  • Humanitas

    Rozzano, Milano, 20089

  • Ospedale S. Matteo degli Infermi

    Spoleto, Perugia, 06049

  • Clinica S. Rita

    Vercelli, 13100

Other trials in Italy

United States4 sites
  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115

  • University of Pennsylvenia Medical Center

    Philadelphia, Pennsylvania, 19104

  • Roger William Medical Centre

    Providence, Rhode Island, 02908

  • Cleveland Clinic Florida

    Weston, Florida, 33331

Other trials in United States

Portugal2 sites
  • General Surgery dept,Hospital Sao Francisco Xavier (CHLO)

    Lisbon

  • Unidade Local de Saúde do Litoral Alentejano (ULSLA)

    Santiago do Cacém, 7500

Other trials in Portugal

Spain2 sites
  • Universidad Miguel Hernández. Elche. Alicante

    Alicante, 03001

  • Hospital Universitario y Politécnico La Fe

    Valencia, 46700

Other trials in Spain

United Kingdom2 sites
  • Dept. of Surgical Oncology - St. Helens Hospital of Liverpool

    Liverpool

  • Manchester Royal Infirmary, University of Manchester

    Manchester

Other trials in United Kingdom

Greece1 site
  • Medical School, Aristotle University of Thessaloniki

    Thessaloniki, 54248

Other trials in Greece

Israel1 site
  • Rabin Medical Center

    Petah Tikva, 4592500

Other trials in Israel

Netherlands1 site
  • Groeningen University Hospital

    Groningen

Other trials in Netherlands

Norway1 site
  • Institute of clinical medicine

    Oslo

Other trials in Norway

Poland1 site
  • Jagiellonian University Medical College

    Krakow

Other trials in Poland

About this study

Official title: GOSAFE Study Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery An International Prospective Audit to Evaluate Postoperative Functional Outcomes and Quality of Life After Cancer Surgery in Geriatric Patients

Multicenter, international, prospective, observational study, designed to evaluate the postoperative results in terms of quality of life and functional recovery of elderly patients after major cancer surgery.

The global expected duration of the study is 3 years, during which cancer patients over 70 years old undergoing major surgery will be evaluated before and after the surgical intervention, at 30 days, 3- and 6-months follow-up. The study is non-for-profit. Given the observational nature of the study, the original treatment plan, as designed by each individual recruiting centre, will not be altered or affected by the study inclusion. Inclusion in the study does not imply any deviation from the current standard of practice, and no change is expected to the perioperative treatment at any point. Patients will be only asked to complete simple screening/assessment tests.

Read the detailed description

GOSAFE study is a prospective international collaborative high-quality registry aiming to gain knowledge about postoperative outcomes in older cancer patients with a particular emphasis on QoL and FR. The target is to obtain meaningful data to assist clinicians in tailoring the care, avoiding under/over-treatment, providing robust data to identify new strategies to improve functional outcomes in older cancer patients.

Recruiting centers will collect data prospectively. Recruited patients will be followed for 6 months after their surgery.

The original treatment plan, as designed by each individual recruiting centre, will not be altered or affected by the study inclusion.

Centers should ensure that they would make every possible effort to include all consecutive eligible patients during the study period and provide completeness of data entry to ensure a 'real-life' study.

Patients both gender, both gender, aged ≥70, affected by solid malignancy undergoing elective major surgical procedures with curative or palliative intent are eligible.

Inclusion in the study does not imply any deviation from the current standard of practice, and no change is expected to the perioperative treatment at any point. Patients will be only asked to complete simple screening/assessment tests.

For every eligible patient, demographic data will be collected at baseline followed by a fast preoperative functional assessment. Data regarding surgical procedures and perioperative measures will be collected. Complications will be reported and graded according to Clavien-Dindo Classification. Three- and six-month follow up data will be collected after surgery within a range of 2 weeks from the due date.

The Full Analysis Set (FAS) consists of all registered patients. The primary endpoint will be measured for all registered subjects who fulfill preoperative and postoperative EQ VAS. Demographic and baseline patient characteristics will be summarized for all patients in the FAS. Continuous-scaled variables (e.g., age) will be summarized with means, medians, standard deviations, quartiles, and minimum and maximum values. Categorical variables (e.g., sex) will be summarized using patient counts and percentages. Study endpoints and variables will be evaluated using descriptive statistics, and the key figures of the distributions will be presented in tables. Univariate analyses will allow for a first overview of potentially influential factors.

Multiple linear regression models will be performed in order to evaluate predictors of functional recovery at 3 months and 6 months after surgery.

Exploratory subgroup analyses will be performed. Missing values will be replaced and estimated using multiple imputations. Furthermore, sensitivity analysis will be executed using complete-case analysis.

A sample size of 265 patients who completed pre and postoperative EQ VAS questionnaires will have a 90% power to detect an effect size of 0,2 between pre and post surgery ,using a paired t-test with a 0,05 two sided significance level.

Given a potential loss to follow-up (about 10%), uncompleted questionnaires (about 10%) and postoperative mortality (about 15%), the sample size will be increased to 350-400 patients (see ref 18 and 19).

Being tested
Questionnaires
Keywords
Surgery, Solid malignancy, Elderly, Functional recovery

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • QuestionnairesOther

    Quality of Life and Functional recovery questionnaires

Study groups in NCT03299270
Study groupRoleWhat they receive
Group 1Elderly patiences with solid malignancy
Receives: Other: Questionnaires

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quality of Life (QoL)

    To evaluate the effects of surgery on patients' life perception by comparing pre- and post-operative QoL in elderly patients undergoing major surgery for solid malignancies using a self-reported Quality of Life assessment tool

    Measured: 6 months

Secondary outcomes (4)
  1. Functional recovery (FR)

    To evaluate FR in terms of nutritional status, restoration of daily activities and cognitive status

    Measured: 6 months

  2. Morbidity

    To evaluate 3 and 6 months postoperative morbidity

    Measured: 6 months

  3. Mortality

    To evaluate 3 and 6 months postoperative mortality

    Measured: 6 months

  4. Prognostic factors

    To obtain prognostic factors for postoperative functional recovery which will assist in the treatment planning /intervention of future elderly patients who are offered surgery for cancer

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Oct 2017
  2. Study start27 Feb 2017
  3. Primary completionFeb 2020 (estimated)
  4. Study completionFeb 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,004 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03299270
Sponsor's protocol ID
GOSAFE
Acronym
GOSAFE
Status last verified
May 2019
First submitted
20 Sep 2017
Last updated
9 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Elderly and Solid Malignancy, run by AUSL ROMAGNA at 28 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 28 sites in Italy, United States, Portugal, Spain, United Kingdom and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quality of Life (QoL) (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in